key: cord-0968382-2tqsete3
authors: Mielke, Dieter; Stanfield‐Oakley, Sherry; Jha, Shalini; Keyes, Taylor; Zalaquett, Adam; Dunn, Brooke; Rodgers, Nicole; Oguin, Thomas; Sempowski, Greg D.; Binder, Raquel A.; Gray, Gregory C.; Karuna, Shelly; Corey, Lawrence; Hural, John; Tomaras, Georgia D.; Pollara, Justin; Ferrari, Guido
title: Development of flow cytometry‐based assays to assess the ability of antibodies to bind to SARS‐CoV‐2‐infected and spike‐transfected cells and mediate NK cell degranulation
date: 2022-04-01
journal: Cytometry A
DOI: 10.1002/cyto.a.24552
sha: e06f6e561a28b9fd31515f3090329ba6ece4693c
doc_id: 968382
cord_uid: 2tqsete3

Since the beginning of the SARS‐CoV‐2 pandemic, antibody responses and antibody effector functions targeting SARS‐CoV‐2‐infected cells have been understudied. Consequently, the role of these types of antibodies in SARS‐CoV‐2 disease (COVID‐19) and immunity is still undetermined. To provide tools to study these responses, we used plasma from SARS‐CoV‐2‐infected individuals (n = 50) and SARS‐CoV‐2 naive healthy controls (n = 20) to develop four specific and reproducible flow cytometry‐based assays: (i) two assessing antibody binding to, and antibody‐mediated NK cell degranulation against, SARS‐CoV‐2‐infected cells and (ii) two assessing antibody binding to, and antibody‐mediated NK cell degranulation against, SARS‐CoV‐2 Spike‐transfected cells. All four assays demonstrated the ability to detect the presence of these functional antibody responses in a specific and reproducible manner. Interestingly, we found weak to moderate correlations between the four assays (Spearman rho ranged from 0.50 to 0.74), suggesting limited overlap in the responses captured by the individual assays. Lastly, while we initially developed each assay with multiple dilutions in an effort to capture the full relationship between antibody titers and assay outcome, we explored the relationship between fewer antibody dilutions and the full dilution series for each assay to reduce assay costs and improve assay efficiency. We found high correlations between the full dilution series and fewer or single dilutions of plasma. Use of single or fewer sample dilutions to accurately determine the response rates and magnitudes of the responses allows for high‐throughput use of these assays platforms to facilitate assessment of antibody responses elicited by SARS‐CoV‐2 infection and vaccination in large clinical studies.

dilutions in an effort to capture the full relationship between antibody titers and assay outcome, we explored the relationship between fewer antibody dilutions and the full dilution series for each assay to reduce assay costs and improve assay efficiency. We found high correlations between the full dilution series and fewer or single dilutions of plasma. Use of single or fewer sample dilutions to accurately determine the response rates and magnitudes of the responses allows for highthroughput use of these assays platforms to facilitate assessment of antibody responses elicited by SARS-CoV-2 infection and vaccination in large clinical studies. with an emergent coronavirus, SARS-CoV [1] , which was most likely generated through sequential recombination and zoonosis [2] . SARS lung pathology studies revealed that alveolar damage was often associated with the presence of multinucleated giant cells, postulated to be a result of syncytia formation [3, 4] . Syncytia can form when Spike (S) protein that is not assembled into virions inside the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) is expressed on the plasma membrane, and interacts with its entry receptor on neighboring cells [5, 6] . SARS-CoV-2, the virus responsible for the COVID-19 pandemic [7] , utilizes the same cellular receptor (ACE2) for entry into host cells as SARS-CoV [8] , and is thought to replicate similarly.

Giant multinucleated cells have also been observed in pulmonary pathology of individuals with COVID-19 [9] . It is therefore likely that SARS-COV-2-infected cells can promote direct cell-to-cell spread of the virus through syncytia formation, providing a rationale for studying immune responses targeting infected cells.

A large amount of effort has been spent in developing assays that can identify the presence of binding and neutralizing antibody responses against SARS-CoV-2, and a large body of literature has been generated characterizing the levels of these antibody functions after infection or vaccination. Although antibody Fc-mediated functions could be effective responses against COVID-19 [10] [11] [12] [13] , we are still facing a significant gap in knowledge on the role of Fc-mediated antibody responses against coronaviruses (CoV), including SARS-CoV-2. The ability of antibodies to bind seasonal CoV-infected cells and mediate antibody-dependent cellular cytotoxicity (ADCC) was reported over 30 years ago in a small study [14] , with follow-up research for SARS-CoV-2 limited to assessments of antibodies that can bind S protein expressed on target cells after transfection [15] [16] [17] or from an engineered stable cell line [18, 19] . None of these studies have investigated the ability of antibodies to bind and mediate ADCC using SARS-CoV-2-infected cells. Given the current pandemic and emergence of novel variants, and awareness of potential future epidemics due to CoV infections, there is a need for detailed assessments of immune responses that may prevent, or promote, COVID-19 with particular emphasis on understanding the role of anti-SARS-CoV-2 antibodies in both non-human primates and human clinical trials. Therefore, we developed assays for detection and measurement of antibody responses that can recognize and engage Fc-Receptorbearing effector cells to eliminate SARS-CoV-2-infected cells.

2 | RESULTS 2.1 | Development of assays to visualize and quantify antibody binding to, and effector functions against, SARS-CoV-2-infected cells

We first studied viral protein expression on the membrane of SARS-CoV-2-infected Vero E6 cells. We used this cell line because of its superior replication capacity compared to human epithelial cell lines, which require longer propagation time in vitro to infection, and its use in most live virus neutralization assays. We determined the expression of viral, and specifically Spike, proteins using both fluorescence microscopy and flow cytometry-based approaches. The same infected cells were used as target cells in an infected cell antibody binding assay and an infected cell antibody-dependent NK cell degranulation assay, which we utilized to detect the presence of ADCC responses ( Figure 1A ). Moreover, we utilized an expression plasmid that encoded the SARS-CoV-2 Spike to transfect 293 cells which were then used as targets in an S-protein-expressing cell antibody binding assay and an Sprotein antibody-dependent NK cell degranulation assay ( Figure 1B ).

These transfection-based assays have the advantage of suitability for BSL-2 laboratories and are easier to scale for higher throughput. The results obtained with each type of target cells were compared to determine the extent to which each assay may provide different and relevant information for the field.

2.2 | Anti-SARS-CoV-2 antibodies can bind to SARS-CoV-2 on the surface of infected cells

We began by using fluorescent microscopy to determine whether SARS-CoV-2 proteins were present on the plasma membrane of infected cells. We first confirmed that SARS-CoV-2 Spike was displayed on the surface of Vero E6 cells which had been infected with SARS-CoV-2 (isolate USA-WA/2020). Surface Spike was stained with anti-SARS-CoV-2 Spike N-Terminal Domain (NTD) antibody, DH1049, isolated from a seroconvalescent individual and infected cells were identified by intracellular staining with a commercially available anti-Nucleocapsid antibody (Figure 2 , in red). We observed binding of DH1049 to the membrane of infected cells (Figure 2 , in green) but we did not detect any binding of the anti-HIV-1 antibody, VRC01, which was used as negative control. To investigate if we could observe plasma antibody binding, we incubated infected cells with plasma (1:100) from a confirmed SARS-CoV-2 infected individual. We found that plasma antibodies from the infected individual bound to infected cells, while no binding was observed when plasma from an uninfected individual was used (Figure 2 ), or in parallel assays performed with mock-infected targets (not shown).

F I G U R E 1 Schematics of the assays developed to assess antibody recognition of SARS-CoV-2 on the surface of infected and transfected cells. Vero E6 cells were infected with SARS-CoV-2 and then incubated with plasma from infected individuals or anti-SARS-CoV-2 spike-specific monoclonal antibodies. Cells were then either stained with fluorescently conjugated anti-IgG and anti-Nucleocapsid antibodies to assess using fluorescent microscopy or flow cytometry, or incubated with NK cells from a healthy human donor to measure the capacity of antibodies to mediate NK cell degranulation (A). For transfected cell assays, 293 cells were transfected with SARS-CoV-2 spike plasmid, incubated with plasma from infected individuals and then stained with fluorescently conjugated anti-IgG to assess using fluorescent microscopy or flow cytometry, or incubated with NK cells from a healthy human donor to measure the capacity of antibodies to mediate NK cell degranulation Using the mean AUC + two standard deviations (SD) of the uninfected subjects, we calculated a positive cut-off value for the assay of AUC > 2.4. Next, we investigated the precision and reproducibility of the assay by repeating a subset of the plasma samples (n = 12 total: n = 10 above the cut-off and n = 2 below the cut-off) three times and found no differences between the assays (Figure S1A [20] . NK cells used in these assays were purified from PBMC of a healthy human donor. The gating strategy used to identify live degranulating NK cells is shown in Figure 4A . Again, to ensure specificity, we used no plasma, plasma from an uninfected individual and plasma from a SARS-CoV-2-infected individual, and incubated samples with NK cells and either mock-infected or SARS-CoV-2-infected cells ( Figure 4B ).

We then used an NK cell degranulation assay to predict cell lysis because it is a strong predictor and prerequisite for ADCC [21] . We above the calculated cut-off and n = 2 below the calculated cut-off) as above and again found no differences between repeats (Figure S1, Kruskal-Wallis p = 0.99) and an average %CV of 11.4% for the 10 samples which were above the cut-off (range: 3.5%-25.9%).

Lastly, we assessed the relationship between binding and degranulation. We found NK cell degranulation only moderately correlated with IgG binding to infected cells ( Figure 5 ;

suggesting that there is an incomplete overlap between these two antibody functions.

Having established that antibodies from SARS-CoV-2-infected individuals were able to bind to infected cells and mediate NK cell degranulation, we proceeded to investigate the extent to which responses to SARS-CoV-2 Spike-transfected cells could be a surrogate to evaluate responses to infected cells. If this is possible, we could reduce our needs to evaluate responses to infected cells that require a BSL-3 environment that is not widely accessible by investigators in the field.

To do this, we developed SARS-CoV-2 Spike-transfected cell binding and degranulation assays ( Figure 1B ship between the two assays, with r s = 0.68 (p < 0.0001, Figure 6C ).

In comparison, the magnitude of antibody-dependent NK cell degranulation detected in the transfected cell and infected cell degranulation assays resulted in a moderate positive relationship (r s = 0.74, p < 0.0001) between the two assays ( Figure 6D ). Lastly, to investigate the extent to which each of the four assays correlated with the other assays, we did a pairwise Spearman correlation ( Figure 6E ). We found that the highest correlation between two assays was the moderate positive relationship observed between the transfected cell and infected cell antibody-dependent NK cell degranulation assays (r s = 0.74). All other Spearman rho's fell between 0.5 and 0.7, suggesting that the assays may be interrelated, but each also detects unique aspects of antibody responses targeting antigen-expressing cells. Figure 7D ). We found a strong correlation (r s = 1.00, p < 0.0001), signifying that these three dilutions accurately represented the full binding curves and could be used in immunogenicity assessment assays.

F I G U R E 4 Legend on next page.

The role of antibody responses targeting SARS-CoV-2-infected cells is understudied and, consequently, undetermined. To provide tools to study these responses, we developed four specific, reproducible assays, each adaptable to circulating SARS-CoV-2 variants, to investigate these responses: two using SARS-CoV-2-infected cells and two using Spike-transfected cells. We show, for the first time, antibody binding to, and antibody mediated NK cell degranulation in the presence of, SARS-CoV-2-infected cells.

We observed, similar to other studies, differences between antibody binding and antibody-mediated NK cell degranulation, suggesting there are different requirements for each function and that each assay will play an important role in deciphering the role of antibody responses against infected cells [19] . While antibodies need to bind to cells to mediate NK cell degranulation, this may not be measured fully by the binding assays, which are cross-sectional and capture only binding events that are present during the limited incubation period of antibodies with infected or Spike-transfected cells.

In comparison, the antibody-mediated NK cell degranulation assays are cumulative and measure events that occur during the entire period of incubation. In addition, differences between the assays may be explained by glycosylation of the antibody Fc or the angle of antibody binding to antigens on infected/transfected cells, which may prohibit Fc binding to the Fc-gamma-receptor IIIA (FcyRIIIA) on NK cells and prevent NK cell degranulation. However, that does not preclude the possibility that binding antibodies that do not mediate NK cell degranulation are facilitating other Fc effector functions such as complement activation or phagocytosis through other immune cells. In addition, the differences observed may be due the binding assays measuring total IgG binding to infected/transfected cells, while individual IgG subclasses are known to contribute differently to antibody effector functions [22, 23] .

We observed quantitative differences in antibody responses to virus-infected and Spike-transfected cells, likely due to the levels of expression of proteins on the cell surface and possibly also due to the presence of antibodies targeting proteins other than the Spike, such as the Nucleocapsid, on the surface of infected cells [24] . The role of antibodies targeting proteins other than Spike is undetermined and requires further study. Conversely, anti-Spike antibodies are of high interest and have been the focus of both passive immunization [25] and vaccination strategies [26] . The focus to date has been on virus or viral protein binding and neutralizing antibodies which have correlated with prevention of transmission and protection from severe disease [27, 28] . However, it is possible these correlates could be, in part, acting as a proxy for Fc functionality. Indeed, the recent correlates' analy- [27] . In addition, another study found that antibody effector functions contributed to monoclonal antibody protection from SARS-CoV-2 protection in hamster and mouse models [29] .

We have already successfully adapted these assays to evaluated vaccine-induced ADCC responses in non-human primates. Interestingly, we found that Spike-transfected cell antibody binding and NK cell degranulation also correlated with reduced viral RNA in a preclinical study that evaluated the effect of adjuvants on a vaccine regimen tested in Rhesus macaques (RM) [30] . These responses were also able to distinguish between groups of RMs that received different adjuvants. Consequently, assays that specifically measure effector 

Vero E6 cells were cultured in MEM (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 μg/ml Penicillin and Streptomycin solution at 37 C and 5% CO 2 . 293T cells were cultured in DMEM (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 μg/ml Penicillin and Streptomycin solution at 37 C and 5% CO 2 . 293F cells were cultured in Freestyle 293 expression media (Thermofisher) at 37 C and 8% CO 2 .

The day before infection, 1 Â After washing, A488-conjugated anti-Human IgG Fc antibody (Clone: HP6017, Biolegend) was added and incubated for 30 min at 4 C on a rocking platform. Cells were then washed and Fluorshield DAPI reagent (Sigma) added before the cover slip was mounted on the slide.

Cells were visualized using a Keyence BZ-X710 fluorescent microscope and images analyzed using BZ-X Analyzer software (v1.3.11).

The binding of anti-SARS-CoV-2 monoclonal antibodies and plasma from SARS-CoV-2-infected individuals to cells was measured as a modification of our previously described procedures [32, 33] . Briefly, 

The Spike-transfected cell antibody binding assay was performed based on our previously described methods [32, 33] , modified to use target cells derived by transfection with plasmids designed to express the SARS-CoV-2 D614 Spike protein with a c-terminus flag tag (kindly provided by Dr. Farzan, Addgene plasmid no. 156420 [34] 

Cell-surface expression of CD107a was used as a marker for NK cell degranulation, a prerequisite process for, and strong correlate of, ADCC [21] , performed by adapting a previously described procedure [20] . 

Area under the curve (AUC) for each assay was calculated from dilution curves using a nonlinear trapezoidal method and dilutions of 1:100, 1:500 and 1:1000. Similarly, the AUC for the Spike-expressing cell antibody binding assay was calculated from a six-dilution curve (50, 100, 500, 1000, 5000 and 10,000) or a three-dilution curve (50, 500 and 5000) using a non-linear trapezoidal method. Correlations between responses from different assays were studied using a Spearman correlation. Differences in responses between two assays were studied using Wilcoxon tests. p values < 0.05 were considered significant. 

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome

Origin and evolution of pathogenic coronaviruses

Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore

Lung pathology of fatal severe acute respiratory syndrome

Coronaviruses: an overview of their replication and pathogenesis

Intracellular targeting signals contribute to localization of coronavirus spike proteins near the virus assembly site

A pneumonia outbreak associated with a new coronavirus of probable bat origin

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

Distinct early serological signatures track with SARS-CoV-2 survival

Discrete SARS-CoV-2 antibody titers track with functional humoral stability

Fab and fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with matrix-M vaccination

Human neutralizing antibodies against SARS-CoV-2 require intact fc effector functions for optimal therapeutic protection

Antibody dependent cellular cytotoxicity against coronavirus 229E-infected cells

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma

Antibodydependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients

A new flow cytometry assay to measure antibody dependent cellular cytotoxicity against SARS-CoV-2 spike expressing cells

The development and kinetics of functional antibody-dependent cellmediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein

HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions

CD107a as a functional marker for the identification of natural killer cell activity

Antibody glycosylation in inflammation, disease and vaccination

Beyond binding: antibody effector functions in infectious diseases

Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals

Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

COVID-19 vaccine efficacy clinical trial

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Pentavalent HIV-1 vaccine protects against simianhuman immunodeficiency virus challenge

An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulation

GDS has a patent application pending for the anti-SARS-CoV-2 mAB, DH1049. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This work was supported by the non-human primate core humoral immunology laboratory for AIDS vaccine Option 28 -Additional effort for COVID-19 (HHSN272201800004C) and the HVTN Laboratory Center: HVTN405 (3 UM1 AI068618-14S1). BSL-3 high containment work was performed in the Duke Regional Biocontainment Laboratory, which received partial support for construction from the NIH/NIAID (AI058607; GDS). DH1049 antibody was isolated with support from a cooperative agreement with DOD/DARPA (HR0011-17-2-0069; GDS).

https://orcid.org/0000-0003-2182-0510